HeartFlow stock: Intrepid Family Office starts $2.7M position

Intrepid Family Office LLC disclosed in a U.S. Securities and Exchange Commission (SEC) Form 13F that it has initiated a position of 110,000 HeartFlow (HTFL) shares, with a reported market value of roughly $2.7 million as of the reporting quarter. The filing covers the period ended December 31, 2025 and was submitted on February 17, 2026.

The 13F information table confirms the holding and places Intrepid among the institutional investors that reported exposure to HTFL in the quarter. Form 13F filings are required quarterly from institutional investment managers over certain asset thresholds and serve as a primary source to track shifts in professional portfolios; data aggregators also index these disclosures for investor monitoring.

While a 110,000-share stake is not large enough by itself to move a newly listed stock materially, the addition underscores rising institutional interest in HeartFlow. Institutional ownership metrics for HTFL show an increase in holders recently, which can amplify price moves during periods of market stress or strong flows; conversely, accumulation by many smaller institutions may not prevent sharp corrections. Market snapshot services report elevated fund participation in HTFL compared with earlier quarters.

HeartFlow completed an upsized initial public offering in 2025 and has attracted financing from several prominent investors through subsequent convertible note and private placements. That financing backdrop, together with investor appetite for healthcare AI plays, helps explain why multiple institutions have taken positions. Ultimately, HeartFlow’s stock performance will remain tied to its ability to translate clinical adoption into sustainable revenue growth and margin expansion.

For investors and analysts, the key takeaway is that 13F disclosures like Intrepid’s are useful directional signals but are backward-looking and reported with a time lag. New or increased institutional positions may prompt further due diligence, yet buyers should weigh company fundamentals, competitive dynamics, and regulatory progress before adjusting their allocations to HTFL. Short-term momentum from institutional buying can support prices, but long-term returns depend on operational execution.